YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1); it significantly inhibits migration, invasion, and tube formation of human umbilical vein endothelial cells (HUVECs) with minimal toxicity; it suppresses VEGF-induced phosphorylation of VEGFR2/KDR/Flk-1 kinase and downstream protein kinases, including extracellular signal-regulated kinase (ERK), focal adhesion kinase (FAK), and Src; it is a potential anti-angiogenic agent candidate for cancer research.